In line with this observation, Takeda and collaborators showed that co-administration of TLR-3-specific RNA agonist and tumor vaccine in combination with anti-PDL1 antibody facilitated tumor regression in mice [36], implying that signaling through this receptor is necessary for the success of the combination. This evidence concerns the gene TLR3 and neoplasm.